- Active Pharmaceutical Ingredients
- 酒石酸伐尼克兰
- Aprepitant, Fosapitant Intermediates
- 福沙匹坦双葡甲胺
- 维格列汀
- 艾氟康唑
- Luliconazole Intermediate
- 钆特酸葡胺
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- 酒石酸伐尼克兰
- 阿瑞匹坦 287930-73-8
- 阿瑞匹坦 127852-28-2
- 阿瑞匹坦 287930-75-0
- 阿瑞匹坦 200000-59-5
- 阿瑞匹坦 155742-64-6
- 阿瑞匹坦 252742-72-6
- 福沙匹坦双葡甲胺 990-91-0
- 福沙匹坦双葡甲胺 265121-01-5
- 维格列汀 207557-35-5
- 维格列汀 702-82-9
- 艾氟康唑 144230-50-2
- 艾氟康唑 133775-25-4
- 艾氟康唑 127000-90-2
- 钆特酸葡胺
- 米拉贝隆
- 卢立康唑 98873-55-3
- 卢立康唑 126534-31-4
- 硫酸阿扎那韦
- 硼替佐米 179324-87-9
- 硼替佐米 114457-94-2
- 硼替佐米 205393-22-2
- 布林佐胺
- 利伐沙 446292-08-6
- 利伐沙 446292-07-5
- 西那卡塞 1005450-55-4
- 西那卡塞 585-50-2
- Eletriptan Intermediate
- 茚达特罗 312753-53-0
- 茚达特罗 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Indate maleate intermediate 173140-90-4
【Catalog number】AP4507
【CAS #】 312753-53-0
【Molecular formula】 C13H20ClN
【Product Brief】CAS 173140-90-4 5- (2R) -2-oxiranyl-8-benzyloxy-2 (1H) -quinolinone, English name is 5- (2R) -2-Oxiranyl- 8-benzyloxy-2 (1H) -quinolinone, American Chemical Abstracts Registration Number is cas 173140-90-4.
5-(2R)-2-Oxiranyl-8-benzyloxy-2(1H)-quinolinone
CAS 173140-90-4
Alias Indate maleate intermediate
Catalog number AP4501
CAS # 173140-90-4
Molecular formula C18H15NO3
Molecular weight 293.31
Structural formula
Product introduction
CAS 173140-90-4 5- (2R) -2-oxiranyl-8-benzyloxy-2 (1H) -quinolinone, English name is 5- (2R) -2-Oxiranyl-
8-benzyloxy-2 (1H) -quinolinone, American Chemical Abstracts Registration Number is cas 173140-90-4.
5- (2R) -2-oxiranyl-8-benzyloxy-2 (1H) -quinolinone (cas 173140-90-4) is an intermediate of indate maleate. Indate maleate is a bronchodilator, belongs to the class of long-acting inhaled β2 receptor agonists (LABA), and is suitable for maintenance treatment of adult patients with chronic obstructive pulmonary disease. Indacaterol has a 5 minute onset and lasts 24 hours. This product is produced by Novartis Pharmaceuticals, Switzerland, and has been marketed in more than 70 countries and regions around the world since 2009; it was approved for listing in China by the State Drug Administration in June 2012 under the trade name Onbrez®.
VIWIT 沪ICP备12014533号-1
